Aptevo Therapeutics Inc.
APVO
NASDAQ·Healthcare·Biotechnology·Mkt cap $3.8M
$1.76
▼ -3.30%
P/E
—
Mkt Cap
$3.8M
52-Wk Range
$1.37–$35.64
52-Week Range
$1.37 - $35.64
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 93.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary ADAPTIR and ADAPTIR-FLEX platform technologies
- Novel bispecific antibody mechanisms targeting multiple validated pathways
- Strategic partnerships with established biotech companies
- Diversified pipeline addressing high-unmet medical needs in oncology
Bear Case
1 risk
- Above-average volatility (beta 1.6).
Growth
Stable outlook
Clinical trial progression of APVO436 for AML and MDS
Value
Valuation data unavailable
Momentum
Falling
-60.6% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying APVO right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 14, 2026
Reported EPS of -$5.31 vs -$6.02 consensus (+11.8% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+11.8%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Citi · Sep 3, 2026
vs Industry
How APVO stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related